RadNet Insider Sells Shares Amid Market Skepticism
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 23 2026
0mins
Should l Buy RDNT?
Source: NASDAQ.COM
- Insider Trading: On March 18, 2026, RadNet's Chief Strategy Officer Gregory Sorensen sold 15,000 shares for approximately $932,000, indicating a cautious outlook on the company's future amidst market volatility.
- Ownership Adjustment: This sale reduced Sorensen's holdings by just over 1%, yet he retains over 1.2 million shares, suggesting he remains aligned with shareholder interests despite the recent stock decline.
- Company Performance Overview: RadNet reported full-year revenue exceeding $2 billion for 2025, an 11.5% increase year-over-year, alongside adjusted EBITDA of $20.8 million, up 7.4%, highlighting the company's growth potential in the medical imaging sector.
- Market Reaction Analysis: Despite solid fundamentals, RadNet's stock has fallen about 12% in 2026, reflecting investor skepticism, prompting a need for careful evaluation of both internal and external factors affecting stock performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RDNT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RDNT
Wall Street analysts forecast RDNT stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 55.740
Low
86.00
Averages
90.17
High
95.00
Current: 55.740
Low
86.00
Averages
90.17
High
95.00
About RDNT
RadNet, Inc. is a national provider of fixed-site diagnostic imaging services in the United States. The Company has a network of 407 owned and/or operated outpatient imaging centers. Its Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. Its Digital Health segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. It provides radiology information technology and artificial intelligence (AI) solutions marketed under the DeepHealth brand and teleradiology professional services. It is also a provider of AI-powered breast health solutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RadNet Executive Sells 15,000 Shares Amid Market Fluctuations
- Executive Sell-Off: Chief Strategy Officer Gregory Sorensen sold 15,000 shares of RadNet on March 18 through multiple open-market transactions, totaling approximately $932,000, resulting in a 1.21% decrease in direct holdings to 1,223,923 shares, indicating a cautious outlook on the company's future.
- Transaction Context: This sale marks Sorensen's only open-market transaction in the past nine months, following a significant sale of 100,000 shares last May, suggesting that current market conditions may be influencing executive decisions, especially as RadNet's stock has declined about 12% in 2026.
- Company Financial Performance: RadNet reported over $2 billion in revenue for 2025, an 11.5% increase year-over-year, alongside adjusted EBITDA of $20.8 million, up 7.4%, highlighting strong growth potential in both its imaging center and digital health segments, with projected 18% revenue growth for the imaging center segment.
- Investor Takeaway: Despite Sorensen's share reduction, he retains over 1.2 million shares, indicating alignment with shareholder interests, and investors should focus on the company's performance in imaging volumes and software growth, as the recent stock decline may reflect market sentiment rather than fundamental changes.
See More
RadNet Insider Sells Shares Amid Market Skepticism
- Insider Trading: On March 18, 2026, RadNet's Chief Strategy Officer Gregory Sorensen sold 15,000 shares for approximately $932,000, indicating a cautious outlook on the company's future amidst market volatility.
- Ownership Adjustment: This sale reduced Sorensen's holdings by just over 1%, yet he retains over 1.2 million shares, suggesting he remains aligned with shareholder interests despite the recent stock decline.
- Company Performance Overview: RadNet reported full-year revenue exceeding $2 billion for 2025, an 11.5% increase year-over-year, alongside adjusted EBITDA of $20.8 million, up 7.4%, highlighting the company's growth potential in the medical imaging sector.
- Market Reaction Analysis: Despite solid fundamentals, RadNet's stock has fallen about 12% in 2026, reflecting investor skepticism, prompting a need for careful evaluation of both internal and external factors affecting stock performance.
See More
Investment Risks and Opportunities in Small-Cap Stocks
- PlayStudios Financial Struggles: PlayStudios (MYPS), with a market cap of $63.05 million, has experienced a 2.7% annual revenue decline over the past five years, indicating market positioning issues, while its free cash flow margin of only 12.8% limits growth investment capabilities, resulting in a stock price of $0.50 and a valuation ratio of 0.3x forward price-to-sales.
- RadNet Operational Challenges: RadNet (RDNT), valued at $4.97 billion, operates over 350 imaging facilities but has a smaller revenue base of $2.04 billion, failing to achieve economies of scale, with adjusted operating margins declining by 3 percentage points; lacking free cash flow restricts reinvestment opportunities, trading at $64.50 per share with a forward P/E of 103.3x.
- Artisan Partners Growth Concerns: Artisan Partners (APAM), with a market cap of $2.50 billion, has shown lackluster sales trends with only 5.9% annual growth over the past five years, trailing behind typical financial firms, and its earnings per share growth of 3.4% lags revenue gains, currently trading at $35.48 per share with a forward P/E of 8.6x, indicating profitability issues.
- Risks in Small-Cap Investments: Small-cap stocks, such as those in the Russell 2000 index, often come with higher volatility and risks, necessitating careful selection by investors; StockStory's research reports assist in identifying better investment opportunities to avoid potential financial pitfalls.
See More
RadNet to Host Investor Conference Call on Acquisition and Digital Health Strategy
- Acquisition Announcement: RadNet will hold a conference call on March 5, 2026, to detail its acquisition of Gleamer SAS, which is expected to enhance its competitive position in the medical imaging sector and drive future revenue growth.
- Digital Health Strategy: During the call, RadNet will share insights into its digital health strategy, particularly focusing on AI-powered health informatics solutions offered under the DeepHealth brand, aimed at improving clinical outcomes and operational efficiency in imaging.
- Investor Engagement Opportunity: Investors will have the chance to ask questions during the call, which not only enhances investor confidence but also provides direct feedback to management, fostering better communication between the company and its investors.
- Global Market Impact: Gleamer's AI solutions have analyzed over 30 million exams across more than 2,250 locations in 44 countries, and RadNet's acquisition is set to further expand its global market share, enhancing its influence in the medical imaging industry.
See More
VentriPoint Partners with LG Consulting for VMS+ Deployment
- Market Potential: The AI medical imaging market is projected to reach nearly $20 billion by 2033, growing at a CAGR of 34.7%, indicating a rapid increase in demand for AI technologies in healthcare, which positions VentriPoint favorably for market share expansion.
- Echocardiography Growth: The echocardiography market is expected to grow to $2.64 billion by 2030, driven by hospitals' dual demand for economic value and clinical accuracy, making VentriPoint's VMS+™ system well-suited to meet this market need.
- Strategic Partnership: The commercial agreement between VentriPoint and LG Consulting Solutions will support the deployment of the VMS+™ system across Northern California, with LG providing economic analysis and clinical implementation support to help hospitals evaluate the economic and clinical value of VMS+™, thereby accelerating technology adoption.
- Demonstration Platform Development: LG Consulting Solutions will purchase a VMS+™ system as a demonstration platform to support hospital engagement, clinician training, and economic value assessments, which not only enhances cardiac care pathways but also presents potential revenue-sharing opportunities for VentriPoint.
See More
VentriPoint Partners with LG Consulting for VMS+ Deployment
- Market Potential: The AI medical imaging market is projected to reach nearly $20 billion by 2033, growing at a CAGR of 34.7%, indicating a rapid increase in demand for AI technologies in healthcare, significantly enhancing VentriPoint's market opportunities.
- Echocardiography Growth: The echocardiography market is expected to grow to $2.64 billion by 2030, driven by hospitals' demand for economic value alongside clinical accuracy, positioning VentriPoint's VMS+™ system to meet this critical need.
- Strategic Partnership: VentriPoint has signed a commercial agreement with LG Consulting Solutions to support the deployment of its VMS+™ system across Northern California, with LG providing economic analysis and clinical implementation support to help hospitals evaluate the economic and clinical value of the technology.
- Demonstration Platform Development: LG Consulting Solutions will purchase a VMS+™ system as a demonstration platform aimed at supporting hospital engagement, clinician training, and economic value assessments, thereby accelerating the adoption of new medical technologies.
See More
RadNet Executive Sells 15,000 Shares Amid Market Fluctuations
- Executive Sell-Off: Chief Strategy Officer Gregory Sorensen sold 15,000 shares of RadNet on March 18 through multiple open-market transactions, totaling approximately $932,000, resulting in a 1.21% decrease in direct holdings to 1,223,923 shares, indicating a cautious outlook on the company's future.
- Transaction Context: This sale marks Sorensen's only open-market transaction in the past nine months, following a significant sale of 100,000 shares last May, suggesting that current market conditions may be influencing executive decisions, especially as RadNet's stock has declined about 12% in 2026.
- Company Financial Performance: RadNet reported over $2 billion in revenue for 2025, an 11.5% increase year-over-year, alongside adjusted EBITDA of $20.8 million, up 7.4%, highlighting strong growth potential in both its imaging center and digital health segments, with projected 18% revenue growth for the imaging center segment.
- Investor Takeaway: Despite Sorensen's share reduction, he retains over 1.2 million shares, indicating alignment with shareholder interests, and investors should focus on the company's performance in imaging volumes and software growth, as the recent stock decline may reflect market sentiment rather than fundamental changes.
See More
RadNet Insider Sells Shares Amid Market Skepticism
- Insider Trading: On March 18, 2026, RadNet's Chief Strategy Officer Gregory Sorensen sold 15,000 shares for approximately $932,000, indicating a cautious outlook on the company's future amidst market volatility.
- Ownership Adjustment: This sale reduced Sorensen's holdings by just over 1%, yet he retains over 1.2 million shares, suggesting he remains aligned with shareholder interests despite the recent stock decline.
- Company Performance Overview: RadNet reported full-year revenue exceeding $2 billion for 2025, an 11.5% increase year-over-year, alongside adjusted EBITDA of $20.8 million, up 7.4%, highlighting the company's growth potential in the medical imaging sector.
- Market Reaction Analysis: Despite solid fundamentals, RadNet's stock has fallen about 12% in 2026, reflecting investor skepticism, prompting a need for careful evaluation of both internal and external factors affecting stock performance.
See More
Investment Risks and Opportunities in Small-Cap Stocks
- PlayStudios Financial Struggles: PlayStudios (MYPS), with a market cap of $63.05 million, has experienced a 2.7% annual revenue decline over the past five years, indicating market positioning issues, while its free cash flow margin of only 12.8% limits growth investment capabilities, resulting in a stock price of $0.50 and a valuation ratio of 0.3x forward price-to-sales.
- RadNet Operational Challenges: RadNet (RDNT), valued at $4.97 billion, operates over 350 imaging facilities but has a smaller revenue base of $2.04 billion, failing to achieve economies of scale, with adjusted operating margins declining by 3 percentage points; lacking free cash flow restricts reinvestment opportunities, trading at $64.50 per share with a forward P/E of 103.3x.
- Artisan Partners Growth Concerns: Artisan Partners (APAM), with a market cap of $2.50 billion, has shown lackluster sales trends with only 5.9% annual growth over the past five years, trailing behind typical financial firms, and its earnings per share growth of 3.4% lags revenue gains, currently trading at $35.48 per share with a forward P/E of 8.6x, indicating profitability issues.
- Risks in Small-Cap Investments: Small-cap stocks, such as those in the Russell 2000 index, often come with higher volatility and risks, necessitating careful selection by investors; StockStory's research reports assist in identifying better investment opportunities to avoid potential financial pitfalls.
See More
RadNet to Host Investor Conference Call on Acquisition and Digital Health Strategy
- Acquisition Announcement: RadNet will hold a conference call on March 5, 2026, to detail its acquisition of Gleamer SAS, which is expected to enhance its competitive position in the medical imaging sector and drive future revenue growth.
- Digital Health Strategy: During the call, RadNet will share insights into its digital health strategy, particularly focusing on AI-powered health informatics solutions offered under the DeepHealth brand, aimed at improving clinical outcomes and operational efficiency in imaging.
- Investor Engagement Opportunity: Investors will have the chance to ask questions during the call, which not only enhances investor confidence but also provides direct feedback to management, fostering better communication between the company and its investors.
- Global Market Impact: Gleamer's AI solutions have analyzed over 30 million exams across more than 2,250 locations in 44 countries, and RadNet's acquisition is set to further expand its global market share, enhancing its influence in the medical imaging industry.
See More
VentriPoint Partners with LG Consulting for VMS+ Deployment
- Market Potential: The AI medical imaging market is projected to reach nearly $20 billion by 2033, growing at a CAGR of 34.7%, indicating a rapid increase in demand for AI technologies in healthcare, which positions VentriPoint favorably for market share expansion.
- Echocardiography Growth: The echocardiography market is expected to grow to $2.64 billion by 2030, driven by hospitals' dual demand for economic value and clinical accuracy, making VentriPoint's VMS+™ system well-suited to meet this market need.
- Strategic Partnership: The commercial agreement between VentriPoint and LG Consulting Solutions will support the deployment of the VMS+™ system across Northern California, with LG providing economic analysis and clinical implementation support to help hospitals evaluate the economic and clinical value of VMS+™, thereby accelerating technology adoption.
- Demonstration Platform Development: LG Consulting Solutions will purchase a VMS+™ system as a demonstration platform to support hospital engagement, clinician training, and economic value assessments, which not only enhances cardiac care pathways but also presents potential revenue-sharing opportunities for VentriPoint.
See More
VentriPoint Partners with LG Consulting for VMS+ Deployment
- Market Potential: The AI medical imaging market is projected to reach nearly $20 billion by 2033, growing at a CAGR of 34.7%, indicating a rapid increase in demand for AI technologies in healthcare, significantly enhancing VentriPoint's market opportunities.
- Echocardiography Growth: The echocardiography market is expected to grow to $2.64 billion by 2030, driven by hospitals' demand for economic value alongside clinical accuracy, positioning VentriPoint's VMS+™ system to meet this critical need.
- Strategic Partnership: VentriPoint has signed a commercial agreement with LG Consulting Solutions to support the deployment of its VMS+™ system across Northern California, with LG providing economic analysis and clinical implementation support to help hospitals evaluate the economic and clinical value of the technology.
- Demonstration Platform Development: LG Consulting Solutions will purchase a VMS+™ system as a demonstration platform aimed at supporting hospital engagement, clinician training, and economic value assessments, thereby accelerating the adoption of new medical technologies.
See More
